Evaluation of the safety of macrolides

International Journal of Antimicrobial Agents

Volumn 18, Issue SUPPL.1, 2001, Pages 77-81

  Williams, J D ^a  

^a UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Laboratory abnormalities; Macrolides; Safety; Side effects

Indexed keywords

ANTIINFECTIVE AGENT; MACROLIDE;

ANIMAL; ANIMAL MODEL; CLINICAL TRIAL; DRUG SCREENING; HUMAN; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; MACROLIDES; MODELS, ANIMAL; TREATMENT OUTCOME;

EID: 4644309299     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0924-8579(01)00399-5     Document Type: Review

References (16)

1. Appel GB. Aminoglycoside nephrotoxicity. Am J Med 1990;88(Suppl. 3C):16S-20S.
2. Amacher DE, Schomaker SJ, Meyers LL. Selective membrane toxicity of aminoglycoside antibiotics in membrane vesicles isolated from proximal renal tubules of the rat. Biochem Pharmacol 1989;38:3867-72.
3. Osono T, Yano K, Mitamoto F, Watanabe S, Ishida H. Studies on josamycin. 3. (1) Bacteriological studies. (2) Protective effect against infections due to pathogenic bacteria. (3) Absorption, excretion, distribution in organs and in vivo activities. Jpn J Antibiot 1969;22:159-72.
4. Krowicki K, Zamojski A. Chemical modification of erythromycins. I. 8,9-anhydro-6,9-hemiketal of erythromycin A. J Antibiot (Tokyo) 1973;26:569-74.
5. Luke DR, Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther 1997;61:641-8.
6. Itoh Z, Suzuki T, Nakaya M, Inoue M, Mitsuhashi S. Gastrointestinal motor-stimulating activity of macrolide antibiotics and analysis of their side effects on the canine gut. Antimicrob Agents Chemother 1984;26:863-9.
7. Braun P. Hepatotoxicity of erythromycin. J Infect Dis 1967;119:300-6.
8. Sullivan D, Csuka ME, Blanchard B. Erythromycin ethylsuccinate hepatotoxicity. J Am Med Assoc 1980;243:1074.
9. Inman WH, Rawson NS. Erythromycin estolate and jaundice. Br Med J (Clin Res Ed) 1983;286:1954-5.
10. Karmody CS, Weinstein L. Reversible sensorineural hearing loss with intravenous erythromycin lactobionate. Ann Otol Rhinol Laryngol 1977;86:9-11.
11. Demaldent JE, Rolland A, Mongrolle Y. Ototoxic potential of erythromycin. Ann Otolaryngol Chir Cervicofac 1984;101:643-7.
12. Haydon RC, Thelin JW, Davis WE. Erythromycin ototoxicity: analysis and conclusions based on 22 case reports. Otolaryngol Head Neck Surg 1984;92:678-84.
13. Sacristan JA, Angeles de Cos M, Soto J, et al. Ototoxicity of erythromycin in man: electrophysiologic approach. Am J Otol 1993;14:186-8.
14. Cortopassi G, Hutchin T. A molecular and cellular hypothesis for aminoglycoside-induced deafness. Hear Res 1994;78:27-30.
15. Sendi PP, Craig BA, Meier G, et al. Cost-effectiveness of azithromycin for preventing Mycobacterium avium complex infection in HIV-positive patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 1999;44:811-7.
16. Jablonowski H, Fatkenheuer G, Youle M, Newell T, Lines S, Craft JC. Ancillary benefites of Mycobacterium civium-inracellulare complex prophylaxis with clarithromycin in HIV-infected patients. Drugs 1997;54(Suppl. 2):16-29.